Rasagiline
Back to searchMolecule Structure
Scientific Name
Rasagiline
Description of the Drug
Rasagiline is an irreversible inhibitor of monoamine oxidase used for the symptomatic management of idiopathic Parkinson’s disease as initial monotherapy and as adjunct therapy to levodopa.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01367
http://www.drugbank.ca/drugs/DB01367
Brand Name(s)
Not Available
Company Owner(s)
Micro Labs Ltd, Apotex Inc, Alkem Laboratories Ltd, Teva Neuroscience Inc, Sandoz Inc, Watson Laboratories Inc, Dr Reddys Laboratories Ltd, Orbion Pharmaceuticals Private Ltd, Aurobindo Pharma Usa Inc, Indoco Remedies Ltd
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Monoamine oxidase B | SINGLE PROTEIN | INHIBITOR | CHEMBL2039 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL74699 | ||||
PharmGKB | PA164764584 | ||||
Human Metabolome Database | HMDB0015454 | ||||
DrugBank | DB01367 | ||||
PubChem: Thomson Pharma | 15219503 | 15120458 | |||
PubChem | 3052776 | ||||
Mcule | MCULE-4385913742 | ||||
LINCS | LSM-45548 | ||||
Nikkaji | J573.894F | ||||
PDBe | RAU | ||||
BindingDB | 10989 | ||||
EPA CompTox Dashboard | DTXSID3041112 | ||||
DrugCentral | 3521 | ||||
Brenda | 143736 | 135328 | 174632 | 163183 | 4421 |
ChemicalBook | CB2459598 | ||||
Guide to Pharmacology | 6641 | ||||
rxnorm | RASAGILINE | ||||
ChEBI | 63620 | ||||
ZINC | ZINC000019875504 |